Stockscreener 앱 받기
54.28
0.63%
0.34
시간 외 거래:
54.28
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
Patrick Lamy Sells 4,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - ACCESS Newswire
Ameriprise Financial Inc. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
15,172 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Ameriprise Financial Inc. - MarketBeat
Bank of America Corp DE Lowers Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Elects New Directors at Annual Meeting - TipRanks
Two Sigma Advisers LP Acquires 27,200 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bank of America Corp DE Has $1.84 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics Brings Breakthrough Metabolic Disease Pipeline to Goldman Sachs Healthcare Conference - Stock Titan
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by Two Sigma Investments LP - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Trading 4.5% HigherStill a Buy? - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2025-06-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AKRO | Press Release - Stockhouse
Nuveen Asset Management LLC Sells 3,385 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00 - MarketBeat
ProShare Advisors LLC Has $623,000 Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Akero Therapeutics Inc. Stock Jumps Over 4%: What’s Powering This Biotech Surge? - Daily Chhattisgarh News
Akero Therapeutics (AKRO) Stock Climbs: Dissecting the Rally and What Lies Ahead - Daily Chhattisgarh News
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse
BNP Paribas Financial Markets Sells 12,220 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.9% Following Insider Selling - MarketBeat
D. E. Shaw & Co. Inc. Sells 89,573 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Woodline Partners LP Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Akero Therapeutics Readies Major Pipeline Updates for Jefferies Healthcare Conference Next Week - Stock Titan
BofA Adjusts Akero Therapeutics (AKRO) Price Target to $64 | AKR - GuruFocus
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00 at Bank of America - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Akero Therapeutics (AKRO) Price Target Raised by B of A Securities | AKRO Stock News - GuruFocus
BofA Adjusts Akero Therapeutics (AKRO) Price Target to $64 | AKRO Stock News - GuruFocus
Rafferty Asset Management LLC Sells 17,797 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 637 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
2025-05-25 | Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AKRO | Press Release - Stockhouse
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
D. E. Shaw & Co. Inc. Decreases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Tema Etfs LLC Makes New $894,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (AKRO) Considers Potential Sale Amid Strategi - GuruFocus
Akero Therapeutics (AKRO) Considers Potential Sale Amid Strategic Interest | AKRO Stock News - GuruFocus
Deutsche Bank AG Has $7.62 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by RTW Investments LP - MarketBeat
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments (NASDAQ:AKRO) - Seeking Alpha
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today - Insider Monkey
Akero Therapeutics (AKRO) Weighs Sale Amid Takeover Interest - GuruFocus
Akero Therapeutics (AKRO) Considers Potential Sale Following Int - GuruFocus
Northern Trust Corp Buys 35,737 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
0.00%
2.33%
자본화:
|
볼륨(24시간):